Human papillomavirus vaccine: Widening the scope for cancer prevention

Molecular Carcinogenesis

Volumn 50, Issue 4, 2011, Pages 244-253

  No, Jae Hong ^a,b   Kim, Mi Kyung ^a   Jeon, Yong Tark ^b   Kim, Yong Beom ^b   Song, Yong Sang ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Human papillomavirus; Prevention; Vaccination

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNIZATION; CLINICAL RESEARCH; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; GROUPS BY AGE; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS CARCINOGENESIS; VULVA CARCINOMA; WART VIRUS;

AGE FACTORS; AGED; ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; MALE; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 79953320609     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20657     Document Type: Article

References (73)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-Key challenges and issues. N Engl J Med 2007; 356: 1908-1910.
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24: S3/11-S3/25.
4. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics 2005; 23: 1107-1122.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
6. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-1589.
7. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-137.
8. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-1919.
9. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001; 61: 1934-1940.
10. Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res 2007; 33: 103-113.
11. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88: 92-98.
12. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148: 2617-2621.
13. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002; 11: 483-488.
14. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc 2007; 297: 813-819.
15. Stanley M. Prophylactic HPV vaccines: Prospects for eliminating anogenital cancer. Br J Cancer 2007; 96: 1320-1323.
16. Ljubojevic S. The human papillomavirus vaccines. Acta Dermatovenerol Croat 2006; 14: 208.
17. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007; 7: 453-459.
18. Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008; 3: e3743.
19. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: A global review. J Adolesc Health 2008; 43: S5-S25.
20. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004; 101: 281-288.
21. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280.
22. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59: 753-757.
23. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM. Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J Infect Dis 2002; 185: 1229-1237.
24. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer 2009; 124: 1626-1636.
25. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
26. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366.
27. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-54.
28. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 2007; 98: 1505-1511.
29. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 2007; 27: 3732-3742.
30. Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004; 18: 2269-2282.
31. Favre-Bonvin A, Reynaud C, Kretz-Remy C, Jalinot P. Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor beta signaling and triggers its degradation by the proteasome. J Virol 2005; 79: 4229-4237.
32. Lu Z, Hu X, Li Y, et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004; 279: 35664-35670.
33. Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 2006; 281: 578-586.
34. Kim SH, Juhnn YS, Kang S, et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci 2006; 63: 930-938.
35. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002; 2: 59-65.
36. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-5949.
37. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947-950.
38. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975-1985.
39. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009; 115: S1-S6.
40. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-4939.
41. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26: K53-K61.
42. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
43. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
44. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
45. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007; 107: S31-S33.
46. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
47. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3: 109-115.
48. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
49. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24: S1-S15.
50. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8.
51. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-1816.
52. Munoz N, Manalastas R, Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 2009; 373: 1949-1957.
53. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194: 1044-1057.
54. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007; 16: 1107-1114.
55. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: The HPV detection in men study. J Infect Dis 2007; 196: 1146-1152.
56. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005; 14: 1710-1716.
57. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004; 31: 601-607.
58. Hippelainen MI, Yliskoski M, Syrjanen S, et al. Low concordance of genital human papillomavirus (HPV) lesions and viral types in HPV-infected women and their male sexual partners. Sex Transm Dis 1994; 21: 76-82.
59. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006; 163: 534-543.
60. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631-639.
61. Kubba T. Human papillomavirus vaccination in the United Kingdom: What about boys? Reprod Health Matters 2008; 16: 97-103.
62. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
63. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-1328.
64. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009; 36: 58-62.
65. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44: 33-40.
66. Wright TC, Jr., Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84: 591-597.
67. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227.
68. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24: S3/140-S3/146.
69. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118: 75S-83S.
70. Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009; 4: 68-73.
71. Bauch CT, Li M, Chapman G, Galvani AP. Adherence to cervical screening in the era of human papillomavirus vaccination: How low is too low? Lancet Infect Dis 2010; 10: 133-137.
72. Myers E, Huh WK, Wright JD, Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 2008; 109: S31-S39.
73. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24: S3/1-S3/10.